ArticleFrontiers in oncology2025
Coexistence of endobronchial aspergilloma, pulmonary embolism, and lung cancer: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endobronchial aspergilloma (EBA) represents an uncommon manifestation of pulmonary aspergillosis that may co-occur with other significant respiratory pathologies, notably lung cancer and pulmonary embolism (PE), complicating diagnosis and management. Case presentation: An 83-year-old male with a history of benign prostatic hyperplasia surgery presented with chest pain. Computed tomography angiography (CTA) of the pulmonary arteries revealed both PE and a left hilar mass. Fiberoptic bronchoscopy disclosed a yellow, mushroom-like lesion, with histological examination confirming squamous cell carcinoma. Subsequent bronchoalveolar lavage culture was positive for Aspergillus flavus, confirming the diagnosis of EBA. Despite initiated treatments, the patient declined further therapeutic interventions and succumbed one month following presentation. Conclusion: This case underscores the rare coexistence of EBA, lung cancer, and PE, highlighting considerable diagnostic challenges and the need for integrated multidisciplinary management strategies in such complex presentations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.